Unknown

Dataset Information

0

Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.

ABSTRACT: We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient's pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

SUBMITTER: Stauble CK 

PROVIDER: S-EPMC8233787 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying <i>CYP2D6</i>*4 Variants: A Case Report.

Stäuble Céline K CK   Lampert Markus L ML   Mikoteit Thorsten T   Hatzinger Martin M   Hersberger Kurt E KE   Meyer Zu Schwabedissen Henriette E HE  

International journal of molecular sciences 20210617 12

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patient  ...[more]

Similar Datasets

Unknown In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database.
| S-EPMC7993315 | biostudies-literature
Unknown Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort.
| S-EPMC4745369 | biostudies-literature
Unknown Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.
| S-EPMC7540972 | biostudies-literature
Unknown Identification of drug-specific public TCR driving severe cutaneous adverse reactions.
| S-EPMC6687717 | biostudies-literature
Transcriptomics Multiomic single-cell sequencing of skin and blister fluid from patients with severe cutaneous adverse drug reactions.
2024-09-18 | GSE275871 | GEO
Unknown Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.
| S-EPMC9976545 | biostudies-literature
Unknown Serious adverse drug reactions at two children's hospitals in South Africa.
| S-EPMC6942333 | biostudies-literature
Unknown Epidemiology of cutaneous adverse drug reactions.
| S-EPMC6039997 | biostudies-other
Unknown Ranking adverse drug reactions with crowdsourcing.
| S-EPMC4387295 | biostudies-other
Unknown Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes.
| S-EPMC8760506 | biostudies-literature